Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

Recruiting now · Not applicable

Conditions studied: Liver Cancer (Primary and Metastatic), Liver Ablation

In brief

Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies

Key facts

Study ID

NCT07459309

Run by

Fudan University

People needed

20

Starts

2026-04-13

Expected to finish

2027-12-31

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 years, regardless of gender;
• Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
• Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
• Patient is intolerant to or refuses surgical resection;
• ECOG performance status score ≤ 2, with an expected survival period of greater than 3 months.

You may not qualify if…

• Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
• Massive or diffuse hepatocellular carcinoma;
• Presence of vascular tumor thrombus or invasion of adjacent organs;
• History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;
• Uncorrectable coagulation dysfunction and severe hematological abnormalities, with a high risk of severe bleeding;
• Refractory massive ascites, cachexia;
• Active infection, especially inflammatory conditions of the biliary system;
• Severe functional failure of major organs such as liver, kidney, heart, lung, and brain;
• Impaired consciousness, or inability to cooperate with treatment;
• Previous systemic treatments (e.g., chemotherapy) with an interval of less than 2 weeks and not having recovered from prior treatment: CTCAE 6.0 grade >1 (except for alopecia);
• Any other factors deemed by the investigator to make the subject unsuitable for participation or to affect the subject's involvement in the study.

Where it is running

• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.